Adnectin-targeted inhibitors: rationale and results.

Abstract	Adnectins are a family of binding proteins derived from the 10th type III domain of human fibronectin (10Fn3), which is part of the immunoglobulin superfamily and normally binds integrin. The 10Fn3 has the potential for broad therapeutic applications given its structural stability, ability to be manipulated, and its abundance in the human body. The most commonly studied adnectin is CT-322, which is an inhibitor of vascular endothelial growth factor receptor-2. A bispecific adnectin, El-Tandem, has also been developed and binds to epidermal growth factor receptor and insulin-like growth factor-1 receptor simultaneously. Pre-clinical studies have shown promising results in relation to reducing tumor growth, decreasing microvessel density, and promoting normalization of tumor architecture. The phase I trial with CT-322 demonstrates relatively low toxicities. However, the phase II study done with CT-322 in recurrent glioblastoma does not reveal as promising results.
Authors	Esha Sachdev, Jun Gong, Bobbie Rimel, Monica Mita
Journal	Current oncology reports (Curr Oncol Rep) Vol. 17 Issue 8 Pg. 35 (Aug 2015) ISSN: 1534-6269 [Electronic] United States
PMID	26045129 (Publication Type: Journal Article)
Chemical References	Angiogenesis Inhibitors Antineoplastic Agents Fibronectins Phosphoinositide-3 Kinase Inhibitors Piperidines Pyrazoles Pyrimidines ibrutinib Thalidomide Bortezomib Vascular Endothelial Growth Factor Receptor-2 Lenalidomide Adenine
Topics	Adenine (analogs & derivatives) Angiogenesis Inhibitors (therapeutic use) Antineoplastic Agents (therapeutic use) Bortezomib (therapeutic use) Clinical Trials as Topic Drug Evaluation, Preclinical Fibronectins (therapeutic use) Humans Lenalidomide Molecular Targeted Therapy (methods) Neoplasms (drug therapy) Phosphoinositide-3 Kinase Inhibitors Piperidines Pyrazoles (therapeutic use) Pyrimidines (therapeutic use) Thalidomide (analogs & derivatives, therapeutic use) Vascular Endothelial Growth Factor Receptor-2 (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!